Search company, investor...

Nabi Biopharmaceuticals

Founded Year



Private Equity | Alive

Total Raised


Last Raised

$33.46M | 19 yrs ago

About Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

Headquarters Location

12276 Wilkins Avenue

Rockville, Maryland, 20852,

United States


Missing: Nabi Biopharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nabi Biopharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nabi Biopharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nabi Biopharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Nabi Biopharmaceuticals Patents

Nabi Biopharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Smoking cessation, Smoking, Tobacco, Substance dependence, Stimulants


Application Date


Grant Date



Related Topics

Smoking cessation, Smoking, Tobacco, Substance dependence, Stimulants



Latest Nabi Biopharmaceuticals News

Biota Pharmaceuticals Inc. formerly Nabi Biopharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Prices from USD $350

Nov 26, 2016

Advertisement Topics   Track topics on Twitter Track topics that are important to you Printed From Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 12:44 EST 26 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals , Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc. since January 2007. Key Findings Provides intelligence on Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Biota Pharmaceuticals, Inc. formerly Nabi Biopharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

Nabi Biopharmaceuticals Frequently Asked Questions (FAQ)

  • When was Nabi Biopharmaceuticals founded?

    Nabi Biopharmaceuticals was founded in 1967.

  • Where is Nabi Biopharmaceuticals's headquarters?

    Nabi Biopharmaceuticals's headquarters is located at 12276 Wilkins Avenue, Rockville.

  • What is Nabi Biopharmaceuticals's latest funding round?

    Nabi Biopharmaceuticals's latest funding round is Private Equity.

  • How much did Nabi Biopharmaceuticals raise?

    Nabi Biopharmaceuticals raised a total of $33.46M.

  • Who are the investors of Nabi Biopharmaceuticals?

    Investors of Nabi Biopharmaceuticals include UBS, Highbridge Capital Management, Dorset Management Corporation, Knott Partners, AWM Investment Company and 11 more.

  • Who are Nabi Biopharmaceuticals's competitors?

    Competitors of Nabi Biopharmaceuticals include Apitope, Sagimet Biosciences, Pfenex, Hawaii Biotech, PaxVax and 11 more.

Compare Nabi Biopharmaceuticals to Competitors

Zetra Biologicals

Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.

Chaperone Technologies

Chaperone Technologies, Inc. is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases. Chaperone's proven technology has already yielded the company's first product, a potent antimicrobial which is in development for treating complicated drug resistant Urinary Tract Infections.


SensiGen is a biotechnology company. They specialize creating tests to screen for diseases more efficiently and quickly. Their goal is to lower the overall costs of diagnosing serious diseases, usually ones where not many diagnostic tests exist.

Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.